Xiaobo Yu

Research Direction: Engaged in proteomics chip technology and precision medicine research. Successfully developed a series of proteomics chips represented by human, tuberculosis and COVID-19 viruses (classic case of the American Chemical Society); established the first human autoantigen database and revealed the formation patterns of autoantigens (Hallmarks of Human Autoantigens); led proteomics research in Chinese and Western medicine clinical cohorts for lung cancer and lymphoma, discovering more than ten original biomarkers.

1. Cheng L#, Wang D#, Wang Z#, Li H, Wang G, Wu Z, Xu M, Yan S, Zhan H, Wang H, Zhang X, Liang T, Wei C, Zhang F, Zheng W*, Yu X*, Li Y*. Proteomic landscape mapping of organ-resolved Behçet’s disease using in-depth plasma proteomics for identifying HABP2 expression associated with vascular damage. Arthritis & Rheumatology. 2023 Mar;75(3):424-437.
2. Zhang X#, Zheng M#, Wang H, Zhou H, Liang T, Zhang J, Ren J, Peng H, Li S, Bian H, Wei C, Yin S, He C, Han Y, Li M, Hou X, Zhang J, Xie L, Lv J, Kan B*, Wang Y*, Yu X*. Inhibitor screening of Spike variants reveals the heterogeneity of neutralizing antibodies to COVID-19 infection and vaccination. Theranotics.2022 12(6):2519-2534.
3. Yang L#, Liang T#, Pierson LM, Wang H, Fletcher JK, Wang S, Bao D, Zhang L, Huang Z, Zheng W, Zhang X, Park H, Li Y, Robinson JE, Feehan AK, Lyon CJ, Cao J, Morici LA, Li C, Roy CJ, Yu X*, Hu T*. SARS-CoV-2 infection and vaccination linear epitopes overlap known neutralizing antibody sites. Research (Wash D C). 2022:9769803.
4. Yu X*,,et al.. Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients. Signal Transduction and Targeted Therapy. 2021 6(1):304.